AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25406267 — intervention group
Group type: COMPARATOR
Intervention: Combination of treadmill and lower-limb resistance supervised exercise training for 12 weeks
Number of subjects: 35
Study 22898999 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 °C water immersion
Number of subjects: 11
Study 22898999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning tasks during 42 °C condition
Number of subjects: 11
Study 22898999 — intervention group
Group type: COMPARATOR
Intervention: 38 °C and 40 °C water immersion
Number of subjects: 11
Study 16785375 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate PDT (160 mg/g; n = 96)
Number of subjects: 225
Study 16785375 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (n = 82)
Number of subjects: 225
Study 16785375 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (5% cream; n = 30)
Number of subjects: 225
Study 12690029 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bedsheets (shukas)
Number of subjects: 472
Study 12690029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 472
Study 10519330 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + GnRH analogue
Number of subjects: 46
Study 10519330 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogue
Number of subjects: 46
Study 7794710 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (10 infants, group B)
Number of subjects: 30
Study 7794710 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (10 infants, group C)
Number of subjects: 30
Study 7794710 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (10 infants, group A)
Number of subjects: 30
Study 7794710 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 infection-free premature infants)
Number of subjects: 30
Study 1826281 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin infusion
Number of subjects: 54
Study 1826281 — intervention group
Group type: COMPARATOR
Intervention: Hemaccel infusion
Number of subjects: 54
Study 6754328 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII treatment
Number of subjects: 60
Study 6754328 — intervention group
Group type: COMPARATOR
Intervention: Control (no factor XIII treatment)
Number of subjects: 60
Study 30670277 — intervention group
Group type: EXPERIMENTAL
Intervention: Frankincense (300 mg)
Number of subjects: 102
Study 30670277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (300 mg)
Number of subjects: 102
Study 30670277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 28704681 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid spineboard
Number of subjects: 12
Study 28704681 — intervention group
Group type: COMPARATOR
Intervention: Soft-layered spineboard
Number of subjects: 12
Study 28704681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both spineboards
Number of subjects: 12
Study 25577973 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine-low volume group
Number of subjects: 163
Study 25577973 — intervention group
Group type: COMPARATOR
Intervention: Control group (liberal hydration)
Number of subjects: 163
Study 23291728 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1650
Study 23291728 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1650
Study 23291728 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in galectin-3 levels over time
Number of subjects: 1650
Study 21338550 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention (n = 67)
Number of subjects: 129
Study 21338550 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 62)
Number of subjects: 129
Study 19050192 — intervention group
Group type: COMPARATOR
Intervention: 0 drinks per day
Number of subjects: 34715
Study 19050192 — intervention group
Group type: EXPERIMENTAL
Intervention: > 0 and < 1 drinks per day
Number of subjects: 34715
Study 19050192 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 1 and < 2 drinks per day
Number of subjects: 34715
Study 19050192 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 2 drinks per day
Number of subjects: 34715
Study 15914074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization-with-movement (MWM)
Number of subjects: 24
Study 15914074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15914074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pooled data)
Number of subjects: 24
Study 12823598 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha combined with ketoprofen (3 million units three times a week and 150 mg twice a day)
Number of subjects: 80
Study 12823598 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha alone (3 million units three times a week)
Number of subjects: 80
Study 12823598 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha combined with ketoprofen
Number of subjects: 80
Study 12823598 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha alone
Number of subjects: 80
Study 10652067 — intervention group
Group type: EXPERIMENTAL
Intervention: Keller Plan (KP)
Number of subjects: 40
Study 10652067 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 8701478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (n = 9)
Number of subjects: 29
Study 8701478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (n = 11)
Number of subjects: 29
Study 8701478 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (n = 9)
Number of subjects: 29
Study 1833898 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 40
Study 1833898 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 40
Study 6137786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 45
Study 6137786 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 45
Study 6137786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31064641 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-PLISSIT model counselling (two 1-hour sessions each week)
Number of subjects: 80
Study 31064641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 80
Study 27208318 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity walking (LW)
Number of subjects: 24
Study 27208318 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple resistance activities (SRA)
Number of subjects: 24
Study 24946982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceram X/Prime&Bond NT
Number of subjects: 456
Study 24946982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram/Optibond Solo Plus
Number of subjects: 456
Study 22421317 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive, church-based, multi-component, motivational enhancement intervention including self-help materials, motivational interviewing calls, newsletters, health promotion activities, and peer support workshops.
Number of subjects: 400
Study 22421317 — intervention group
Group type: COMPARATOR
Intervention: Control group (churches not receiving the intervention).
Number of subjects: 400
Study 19084115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone delivery system (HealOzone; KaVo, Biberach, Germany)
Number of subjects: 44
Study 19084115 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study 17449592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15 mg retinol equivalent)
Number of subjects: 1077
Study 17449592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 1077
Study 15858816 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation workshops (6 workshops, 3 hours each)
Number of subjects: 62
Study 12789993 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel (18% carbamide peroxide)
Number of subjects: 97
Study 12789993 — intervention group
Group type: COMPARATOR
Intervention: Commercially available whitening dentifrice
Number of subjects: 97
Study 9607830 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate (750 mg and 1000 mg three times daily)
Number of subjects: 65
Study 9607830 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate (open-label extension with nucleoside inhibitors of reverse transcriptase)
Number of subjects: 65
Study 7883843 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 28
Study 7883843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2136198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative air testing (test group)
Number of subjects: 143
Study 2136198 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative air testing (no test group)
Number of subjects: 143
Study 355182 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 40
Study 355182 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 40
Study 30541378 — intervention group
Group type: EXPERIMENTAL
Intervention: Mums Step It Up (MSIU) Facebook app (n=41)
Number of subjects: 120
Study 30541378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer only (n=39)
Number of subjects: 120
Study 30541378 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 120
Study 26044933 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmakinetic vapor enucleation of the prostate (PVEP)
Number of subjects: 112
Study 26044933 — intervention group
Group type: COMPARATOR
Intervention: Plasmakinetic resection of the prostate (PKRP)
Number of subjects: 112
Study 26044933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PVEP and PKRP
Number of subjects: 112
Study 23547971 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard time-based Green Prescription
Number of subjects: 225
Study 23547971 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pedometer-based Green Prescription
Number of subjects: 225
Study 22242350 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) at 3.5 W
Number of subjects: 60
Study 22242350 — intervention group
Group type: COMPARATOR
Intervention: High-intensity focused ultrasound (HIFU) at 4.0 W (Group B)
Number of subjects: 60
Study 22242350 — intervention group
Group type: COMPARATOR
Intervention: High-intensity focused ultrasound (HIFU) at 4.5 W (Group C)
Number of subjects: 60
Study 19699334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial PCI with maximal antiplatelet therapy (aspirin, clopidogrel, and abciximab)
Number of subjects: 1348
Study 16449108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic St. John's wort extract and isopropanolic black cohosh extract
Number of subjects: 301
Study 16449108 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 301
Study 15566422 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg daily for 14 days
Number of subjects: 28
Study 15566422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11553137 — intervention group
Group type: EXPERIMENTAL
Intervention: Excipial Protect (containing aluminium chlorohydrate 5%)
Number of subjects: 0
Study 11553137 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study 8985259 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 86
Study 8985259 — intervention group
Group type: COMPARATOR
Intervention: Normolipidemic subjects
Number of subjects: 86
Study 7691342 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental teaching procedures; utilized in a multiple-baseline fashion across three sequential environments.
Number of subjects: 0
Study 3084952 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (1.4-2.0 g/kg body weight, two doses)
Number of subjects: 12
Study 3084952 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (two doses in the morning)
Number of subjects: 12
Study 3084952 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch (2-3 g/kg body weight every 6 hours)
Number of subjects: 12
Study 29544870 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061
Study 29544870 — intervention group
Group type: COMPARATOR
Intervention: Canakinumab (all doses)
Number of subjects: 10061
Study 29544870 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 10061
Study 27353607 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated patient information
Number of subjects: 0
Study 27353607 — intervention group
Group type: COMPARATOR
Intervention: Baseline model of overall mortality
Number of subjects: 0
Study 27353607 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated model
Number of subjects: 0
Study 25522731 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training plus telephone consultation
Number of subjects: 0
Study 25522731 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training only
Number of subjects: 0
Study 25522731 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study 22301107 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-releasing implants
Number of subjects: 105
Study 22301107 — intervention group
Group type: COMPARATOR
Intervention: Non-drug-releasing implants
Number of subjects: 105
Study 20044472 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW‐CHO
Number of subjects: 9
Study 20044472 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW‐EN
Number of subjects: 9
Study 20044472 — intervention group
Group type: COMPARATOR
Intervention: BAL
Number of subjects: 9
Study 20044472 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 9
Study 18842753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for depression
Number of subjects: 1233
Study 18842753 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 1233
Study 16364862 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 monitoring of cyclosporine levels
Number of subjects: 125
Study 16364862 — intervention group
Group type: COMPARATOR
Intervention: C0 monitoring of cyclosporine levels
Number of subjects: 125
Study 11805583 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg per day)
Number of subjects: 21796
Study 11805583 — intervention group
Group type: COMPARATOR
Intervention: Dietary vitamins C and E and beta‐carotene
Number of subjects: 21796
Study 11805583 — intervention group
Group type: COMPARATOR
Intervention: Long‐term vitamin E and beta‐carotene supplementation
Number of subjects: 21796
Study 10409572 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dexamethasone
Number of subjects: 24
Study 10409572 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexamethasone
Number of subjects: 24
Study 10409572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7589024 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 70
Study 7589024 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5, 10, or 15 mg)
Number of subjects: 70
Study 7589024 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg or 0.25 mg)
Number of subjects: 70
Study 7589024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2260872 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dl-Leucovorin (500 mg/m2) and 5-FU (600 mg/m2)
Number of subjects: 61
Study 6768078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin self-administration with naltrexone placebo
Number of subjects: 11
Study 6768078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin self-administration with buprenorphine placebo
Number of subjects: 11
Study 6768078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin self-administration
Number of subjects: 11
Study 6768078 — intervention group
Group type: COMPARATOR
Intervention: Baseline and heroin conditions
Number of subjects: 11
Study 6669628 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 20
Study 6669628 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 20
Study 6669628 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (0.5 g/kg body weight)
Number of subjects: 20
Study 6669628 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone plus Alcohol
Number of subjects: 20
Study 6669628 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam plus Alcohol
Number of subjects: 20
Study 6669628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30102686 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery Group (ARG)
Number of subjects: 14
Study 30102686 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery Group (PRG)
Number of subjects: 14
Study 29282360 — intervention group
Group type: EXPERIMENTAL
Intervention: High total serum cholesterol
Number of subjects: 4974
Study 29282360 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL
Number of subjects: 4974
Study 29282360 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL levels
Number of subjects: 4974
Study 26815931 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized Optical Coherence Tomography (OCT)
Number of subjects: 0
Study 26815931 — intervention group
Group type: COMPARATOR
Intervention: Centralized photography suite (Control)
Number of subjects: 0
Study 24650448 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/d
Number of subjects: 780
Study 22817651 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (Group B)
Number of subjects: 240
Study 22817651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 240
Study 22817651 — intervention group
Group type: COMPARATOR
Intervention: Clamping of drain with placebo (Group D)
Number of subjects: 240
Study 22817651 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamping of drain with tranexamic acid (Group D)
Number of subjects: 240
Study 19815376 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention/mindfulness induction
Number of subjects: 0
Study 19815376 — intervention group
Group type: COMPARATOR
Intervention: Unfocused attention induction
Number of subjects: 0
Study 17961428 — intervention group
Group type: EXPERIMENTAL
Intervention: Brugada syndrome patients
Number of subjects: 23
Study 17961428 — intervention group
Group type: COMPARATOR
Intervention: Brugada syndrome patients without cardiac events
Number of subjects: 23
Study 16140230 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home exercise programme (twice-weekly for 6 weeks)
Number of subjects: 31
Study 16140230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 31
Study 12096962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost and 0.5% timolol combination therapy
Number of subjects: 418
Study 12096962 — intervention group
Group type: COMPARATOR
Intervention: 0.005% latanoprost monotherapy
Number of subjects: 418
Study 12096962 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol monotherapy
Number of subjects: 418
Study 10445599 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 250 microg, two puffs b.i.d. for 6 weeks
Number of subjects: 40
Study 7798505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (25 mg of aspirin and 200 mg of dipyridamole twice daily)
Number of subjects: 215
Study 7798505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 7798505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 215
Study 2346545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenticonazole 2% cream
Number of subjects: 12
Study 2346545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenticonazole spray
Number of subjects: 12
Study 2346545 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole 2% cream
Number of subjects: 12
Study 2346545 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole 1% spray
Number of subjects: 12
Study 393378 — intervention group
Group type: EXPERIMENTAL
Intervention: PACe (Cis-dichlorodiammineplatinum(II) 80 mg/m2 iv Day 1, Adriamycin 40 mg/m2 iv Day 1, cyclophosphamide 200 mg/m2 orally Days 2-5)
Number of subjects: 28
Study 393378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) (CDDP) alone (80 mg/m2 Day 1)
Number of subjects: 28
Study 393378 — intervention group
Group type: COMPARATOR
Intervention: Cis-dichlorodiammineplatinum(II) (CDDP)
Number of subjects: 28
Study 28570491 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training)
Number of subjects: 20
Study 28570491 — intervention group
Group type: COMPARATOR
Intervention: CT (Continuous Training)
Number of subjects: 20
Study 29400014 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with oral MPA (400-600 mg/day)
Number of subjects: 244
Study 29400014 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated treatment with oral MPA (400-600 mg/day)
Number of subjects: 244
Study 27998860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral blockade (group A, n=60)
Number of subjects: 120
Study 27998860 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with tracheal intubation (group B, n=60)
Number of subjects: 120
Study 24390871 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured heart failure education program
Number of subjects: 0
Study 24390871 — intervention group
Group type: COMPARATOR
Intervention: Single lecture on the disease (Control)
Number of subjects: 0
Study 23033884 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/day)
Number of subjects: 78
Study 23033884 — intervention group
Group type: COMPARATOR
Intervention: nothing (control)
Number of subjects: 78
Study 19667111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 19667111 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin neutralizing antibody
Number of subjects: 0
Study 19667111 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocyte conditioned medium
Number of subjects: 0